Avastin Study Shows No Extension of Patient Lives with Breast Cancer

In order for life extension provisions to apply tumor shrinkage is taken into consideration. Avastin is still FDA approved but whether or not it it stays, time will tell. Avastin is also approved for other types of cancer and is used in combination with chemotherapy. BD

WASHINGTON (AP) — U.S. government health scientists said Friday that follow-up studies of a Roche breast cancer drug show it failed to slow tumor growth or extend patient lives, opening the door for a potential withdrawal in that indication.

Additionally, the FDA said more recent data did not confirm the tumor shrinkage seen in earlier studies.

Patients taking Avastin showed significantly more side effects, including high blood pressure, fatigue and abnormal white blood cell levels.

On Tuesday the FDA will ask a panel of outside cancer experts to review the evidence on Avastin. The panel's recommendations are not binding, but the FDA usually follows their guidance.

The FDA has the option to remove drug's approval for breast cancer.